ADSS1
protein-codingadenylosuccinate synthase 1
Gene summary
This gene encodes a member of the adenylosuccinate synthase family of proteins. The encoded muscle-specific enzyme plays a role in the purine nucleotide cycle by catalyzing the first step in the conversion of inosine monophosphate (IMP) to adenosine monophosphate (AMP). Mutations in this gene may cause adolescent onset distal myopathy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2016]
- ADSSL1
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~23.2 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0014877
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0014877
Submitter: Labcorp Genetics (formerly Invitae)
Clinical Genomic Database (CGD)
Manifestation: Musculoskeletal
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to ADSS1 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_152328.5. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | 87 | 3 | 91 | ||
| missense | 1 | 3 | 184 | 3 | 3 | 194 |
| nonsense | 4 | 1 | 5 | |||
| start loss | 0 | |||||
| frameshift | 5 | 4 | 3 | 12 | ||
| splice donor/acceptor (+/-2bp) | 2 | 11 | 5 | 18 | ||
| Total | 12 | 19 | 193 | 90 | 6 | 320 |
Highest pathogenic variant AF is 0.00018038614
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_689541.1 | 13 | MANE Select | |
| Ensembl | ENSP00000331260.2 | 13 | MANE Select | |
| RefSeq | NP_001307353.1 | 7 | Standard | |
| RefSeq | NP_954634.1 | 13 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| adssl1 | Danio rerio | Structure: skeletal muscle cell Quality: apoptotic abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Alanine, aspartate and glutamate metabolism - Homo sapiens (human)
- Purine metabolism - Homo sapiens (human)
- Hypoacetylaspartia
- Aspartate Metabolism
- Canavan Disease
Biological Process
- immune system process
- AMP biosynthetic process
- aspartate metabolic process
- glutamine metabolic process
- purine ribonucleoside monophosphate biosynthetic process
Molecular Function
- magnesium ion binding
- GTPase activity
- adenylosuccinate synthase activity
- GTP binding
- phosphate ion binding
Cellular Component
- cytoplasm
- cytosol
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000332972
- Coding exons
- 13
- Length
- 23140
- Individuals with no LoFs
- 125578
- Homozygous LoFs
- 2
- Heterozygous LoFs
- 168
- Defined
- 125748
- p
- 0.000676
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | -0.0328 | 306 | 304 | 1.01 | 0.0000184 | 3206 |
| Missense (PolyPhen) | 148 | 139.96 | 1.0574 | 1315 | ||
| Synonymous | 0.811 | 117 | 129 | 0.909 | 0.00000874 | 1007 |
| Loss of Function | 2.20 | 15 | 27.4 | 0.547 | 0.00000145 | 294 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00043 | 0.00043 | rare |
| Latino/Admixed American | 0.0016 | 0.0016 | notable |
| Ashkenazi Jewish | 0.00099 | 0.00099 | rare |
| East Asian | 0.0013 | 0.0013 | notable |
| Finnish | 0.000092 | 0.000092 | rare |
| European (Non-Finnish) | 0.00047 | 0.00046 | rare |
| South Asian | 0.00056 | 0.00052 | rare |
| Other | 0.00049 | 0.00049 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Component of the purine nucleotide cycle (PNC), which interconverts IMP and AMP to regulate the nucleotide levels in various tissues, and which contributes to glycolysis and ammoniagenesis. Catalyzes the first committed step in the biosynthesis of AMP from IMP. {ECO:0000269|PubMed:26506222}.;
Recessive Scores
- pRec
- 0.155
Intolerance Scores
- LoFtool
- 0.875
- RVIS EVS
- -0.02
- RVIS percentile EVS
- 52.25
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- S
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.683
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |